WSJ
01 Sept 2026, 04:14 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
1 claim · each scored for market impact
Novartis paused eight clinical trials of an experimental therapy for autoimmune and neurological disorders following three patient deaths. — Patient fatalities and the subsequent halting of multiple trials represent a significant clinical failure and potential loss of future revenue streams.
-0.80Which stocks this story touches
The company paused eight clinical trials following three patient deaths.
Continue reading
6 related stories
Top 1 mover · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
5d ago
